Burden and rates of treatment and control of cardiovascular disease risk factors in obesity - The Framingham Heart Study

被引:47
|
作者
Molenaar, Esther A. [2 ,3 ]
Hwang, Shih-Jen [4 ]
Vasan, Ramachandran S. [5 ]
Grobbee, Diederick E. [2 ]
Meigs, James B. [6 ,7 ]
D'Agostino, Ralph B. [8 ]
Levy, Daniel [4 ]
Fox, Caroline S. [1 ]
机构
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Endocrinol Diabet & Hypertens, Boston, MA 02115 USA
[2] Univ Utrecht, Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
[3] Municipal Hlth Serv Utrecht, Utrecht, Netherlands
[4] NHLBI, Framingham Heart Study, Framingham, MA USA
[5] Boston Univ, Sch Med, Dept Cardiol & Prevent Med, Boston, MA 02118 USA
[6] Massachusetts Gen Hosp, Div Gen Internal Med, Boston, MA 02114 USA
[7] Harvard Univ, Sch Med, Boston, MA 02115 USA
[8] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA
关键词
D O I
10.2337/dc07-2413
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE - Obesity is associated with an increased risk for cardiovascular disease (CVD). We sought to determine rates of treatment and control of CVD risk factors among normal weight, over-weight, and obese individuals in a community-based cohort. RESEARCH DESIGN AND METHODS - Participants free of CVD (n = 6,801; mean age 49 years; 54% women) from the Framingham Offspring and Third Generation cohorts who attended the seventh Offspring examination (1998-2001) or first Third Generation (2002-2005) examination were studied. RESULTS - Obese participants with hypertension were more likely to receive antihypertensive treatment (62.3%) than normal weight (58.7%) or overweight (59.0%) individuals (P = 0.002), but no differences in hypertension control across BMI subgroups among participants with hypertension were observed (36.7% [normal weight], 37.3% [overweight], and 39.4% [obese]; P = 0.48). Rates of lipid-lowering treatment were higher among obese participants with elevated LDL cholesterol (39.5%) compared with normal weight (34.2%) or overweight (36.4%) participants (P = 0.02), but control rates among those with elevated LDL cholesterol did not differ across BMI categories (26.7% [normal weight], 26.0% [overweight], and 29.2% [obese]; P = 0.11). There were no differences in diabetes treatment among participants with diabetes across BMI groups (69.2% [normal weight], 50.0% [overweight], 55.0% [obese]; P = 0.54), but obese participants with diabetes were less likely to have fasting blood glucose <126 mg/dl (15.7%) compared with normal weight (30.4%) or overweight (20.7%) participants (P = 0.02). CONCLUSIONS - These findings emphasize the suboptimal rates of treatment and control of CVD risk factors among overweight and obese individuals.
引用
收藏
页码:1367 / 1372
页数:6
相关论文
共 50 条
  • [21] Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study
    Parikh, Nisha I.
    Gona, Philimon
    Larson, Martin G.
    Wang, Thomas J.
    Newton-Cheh, Christopher
    Levy, Daniel
    Benjamin, Emelia J.
    Kannel, William B.
    Vasan, Ramachandran S.
    EUROPEAN HEART JOURNAL, 2007, 28 (21) : 2644 - 2652
  • [22] Trends in diabetes as a cardiovascular disease risk factor: The Framingham Heart Study
    Fox, CS
    Coady, S
    Sorlie, PD
    D'Agostino, RB
    Vasan, RS
    Meigs, JB
    Levy, D
    Savage, PJ
    CIRCULATION, 2005, 112 (17) : U856 - U856
  • [23] Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham Heart Study
    Fox, Caroline S.
    Pencina, Michaei J.
    Wilson, Peter W. F.
    Paynter, Nina P.
    Vasan, Ramachandran S.
    D'agostino, Ralph B.
    DIABETES CARE, 2008, 31 (08) : 1582 - 1584
  • [24] Peri-aortic fat, cardiovascular disease risk factors, and aortic calcification: The Framingham Heart Study
    Lehman, Sam J.
    Massaro, Joseph M.
    Schlett, Christopher L.
    O'Donnell, Christopher J.
    Hoffmann, Udo
    Fox, Caroline S.
    ATHEROSCLEROSIS, 2010, 210 (02) : 656 - 661
  • [25] EFFECTS OF ANTIHYPERTENSIVE TREATMENT ON CARDIOVASCULAR RISK-FACTORS - DATA FROM THE FRAMINGHAM HEART-STUDY
    SHEA, S
    COOK, EF
    KANNEL, WB
    GOLDMAN, L
    CIRCULATION, 1983, 68 (04) : 286 - 286
  • [26] Association of circulating endothelial microparticles with cardiovascular risk factors in the Framingham Heart Study
    Amabile, N.
    Cheng, S.
    Larson, M. G.
    Ghorbani, A.
    Mc Cabe, E.
    Griffin, G.
    Cohen, K. S.
    Tedgui, A.
    Boulanger, C. M.
    Wang, T. J.
    EUROPEAN HEART JOURNAL, 2012, 33 : 344 - 344
  • [27] ASSESSMENT OF CARDIOVASCULAR RISK-FACTORS IN THE ELDERLY - THE FRAMINGHAM HEART-STUDY
    LARSON, MG
    STATISTICS IN MEDICINE, 1995, 14 (16) : 1745 - 1756
  • [28] Association Between Prolactin and Incidence of Cardiovascular Risk Factors in the Framingham Heart Study
    Therkelsen, Kate E.
    Abraham, Tobin M.
    Pedley, Alison
    Massaro, Joseph M.
    Sutherland, Patrice
    Hoffmann, Udo
    Fox, Caroline S.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (02): : 1 - 10
  • [29] The burden of cardiovascular risk factors and coronary heart disease in Europe and worldwide
    Vilahur, Gemma
    Badimon, Juan Jose
    Bugiardini, Raffaele
    Badimon, Lina
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2014, 16 (0A) : A7 - A11
  • [30] High normal blood pressure and risk of cardiovascular disease: The Framingham heart study
    Vasan, RS
    Larson, MG
    Evans, JC
    O'Donnell, CJ
    Levy, D
    CIRCULATION, 1999, 100 (18) : 34 - 34